1 / 43

Carcinomas

Carcinomas. Wendy Blount, DVM. Carcinomas. Squamous cell carcinoma (canine & feline) Transitional c ell carcinoma (canine) Mammary Gland Tumor (canine & feline) Perianal tumor (canine) Anal sac tumors ( c anine). Squamous Cell Carcinoma. Feline Squamous Cell carcinoma

lenka
Download Presentation

Carcinomas

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Carcinomas Wendy Blount, DVM

  2. Carcinomas • Squamous cell carcinoma (canine & feline) • Transitional cell carcinoma (canine) • Mammary Gland Tumor (canine & feline) • Perianal tumor (canine) • Anal sac tumors (canine)

  3. Squamous Cell Carcinoma Feline Squamous Cell carcinoma • Second most common tumor in the cat • Oral SCC behaves differently than skin SCC Canine Squamous Cell Carcinoma • Similar behavior as SCC in cats, but not as common

  4. Squamous Cell Carcinoma Feline Cutaneous Squamous Cell Carcinoma • Most frequently on the head • Pinnae, nose, eyelids • Caused by sun exposure to light colored skin • Progression over time • Solar dermatitis – crusts and scabs • Actinic dermatitis - plaques • SCC in situ – noninvasive mass • Invasive SCC – ulcerative, invasive mass

  5. Squamous Cell Carcinoma Feline Cutaneous Squamous Cell Carcinoma Actinic dermatitis Solar dermatitis

  6. Squamous Cell Carcinoma Feline Cutaneous Squamous Cell Carcinoma SCC SCC n situ

  7. Squamous Cell Carcinoma Feline Cutaneous Squamous Cell Carcinoma • Cytology often not helpful • Very inflammatory • Dx - histopathology • Staging not usually necessary, as metastasis is rare • Tx – early lesions • Surgery, cryosurgery, Strontium radiotherapy, photodynamic therapy • immunomodulatory agent imiquimod (AldaraTM) as a topical cream

  8. Squamous Cell Carcinoma Feline Cutaneous Squamous Cell Carcinoma • Tx – advanced lesions • Difficult to treat • Removal of the nasal planum is possible, but disfiguring

  9. Squamous Cell Carcinoma Feline Cutaneous Squamous Cell Carcinoma Pinnectomy and planectomy Partial planectomy

  10. Squamous Cell Carcinoma Feline Cutaneous Squamous Cell Carcinoma Untreated for too long

  11. Squamous Cell Carcinoma Feline Oral Squamous Cell Carcinoma • Most common oral tumor in the cat • Gingiva, tongue/sublingual, tonsil • Much more aggressive than cutaneous SCC • Maxillary tumors can mimic tooth abscess • Surgery often not possible • Radiation sensitive, but high morbidity – mandatory feeding tube

  12. Squamous Cell Carcinoma Feline Oral Squamous Cell Carcinoma • Chemotherapy not effective • NSAIDs are palliative • Median survival 44 days + NSAIDs • 9% survival at one year • Survival more than a few months even with multimodal therapy is rare

  13. Squamous Cell Carcinoma Feline Lung Squamous Cell Carcinoma • Often presents as multiple nail bed tumors • Primary tumor is found on chest x-rays • Always take chest x-rays prior to amputating a possibly neoplastic nail bed in a cat • Animals with systemic neoplasia often do not do well under anesthesia • Amputation is palliative only

  14. Transitional Cell Carcinoma • Most common bladder tumor in the dog (90%) • Most common symptoms are hematuria and stranguria • Things that increase suspicion • Atypical transitional cells in the urine sediment • Mass in the bladder or urethra on imaging • Thickened urethra on rectal exam • Ruptured urethra on catheterization

  15. Transitional Cell Carcinoma Etiology • Exposure to older topical flea treatments, dips and lawn chemicals (28x) • Possibly cyclophosphamide therapy • Neutered > sexually intact • Scottish terriers 18-20x other dog breeds • Eating vegetables 3x a week is protective • Shelties, Westies, beagles 3-5x other breeds

  16. Transitional Cell Carcinoma Dx – histopath • Surgery, cystoscopy, traumatic bladder wash • Percutaneous aspiration can seed tumor cells and should be avoided • Take care to avoid seeding during surgery

  17. Transitional Cell Carcinoma Tx • At one time, radiation therapy was recommended, as TCC is highly responsive • But resulting permanent incontinence was common • If at the apex, resection can produce long disease free interval (1-2 years) • Secondary UTI is common – treat PRN • Ureteral stents can restore urine flow • Urethral stents can relieve obstruction if urethral sphincter and continence can be preserved • Prepubic cystostomy tube can relieve obstruction

  18. Transitional Cell Carcinoma Tx - NSAIDs • Mainstay of treatment is medical therapy • Not curative, but remission is achieved in 15-20% and stable disease is reached in 75% of dogs • Piroxicam only – median survival 195 days • 0.3 mg/kg PO SID to QOD • Deramaxx only - median survival 323 days • 3 mg/kg PO SID • Previcox similar success • Median survival surgery only is 109 days

  19. Transitional Cell Carcinoma Tx - Chemo • Mitoxantrone and piroxicam (see chemo section for details) • 35% remission with minimal toxicity • Median survival 291 days • Single agent vinblastine (see MCT notes) • 36% remission • 50% stable disease • Most of these had failed other therapies • Relatively more toxicity than mitoxantrone + piroxicam

  20. Transitional Cell Carcinoma Px • Euthanasia often due to obstruction, metastasis or both • 50% have metastasis at the time of death • Some will invade the sublumbar lymph nodes and then the spinal cord and present as acute posterior paralysis, often with urethral obstruction

  21. Canine Mammary Gland Tumor • 42% of tumors in all intact female dogs • Rare in dogs less than 5 years old • duration of exposure to ovarian hormones early in life determines the overall mammary cancer risk (Dorn et al, 1968). • 0.5% if OHE prior to the first heat • 8 if OHE prior to the 2nd heat • 26% if OHE after the 2nd heat • tumor risk increases incrementally each year and plateaus around 11–13 (Schneider, 1970) • intact females are more likely to have an anaplastic tumor type, compared to dogs spayed early or late in life, prior to MGT (Ogilvie, 2006)

  22. Canine Mammary Gland Tumor The effect of neutering on the risk of mammary tumours in dogs--a systematic review. J Small AnimPract. June 2012;53(6):314-22. W Beauvais1; J M Cardwell; D C Brodbelt Due to the limited evidence available and the risk of bias in the published results, the evidence that neutering reduces the risk of mammary neoplasia, and the evidence that age at neutering has an effect, are judged to be weak and are not a sound basis for firm recommendations.

  23. Canine Mammary Gland Tumor • Review article – not a clinical study at all • Conclusions: • 9/13 were judged to have a high risk of bias. The remaining four were classified as having a moderate risk of bias. • One study found an association between neutering and a reduced risk of mammary tumours. • Two studies found no evidence of an association. • One reported "some protective effect" of neutering on the risk of mammary tumours

  24. Canine Mammary Gland Tumor • 70% have more than one tumor at the time of diagnosis • Mammary gland tumors can be epithelial, myoepithelial, mesenchymal or mixed • Complex MGT – epithelial and myoepithelial • Mixed MGT – epithelial and mesenchymal

  25. Canine Mammary Gland Tumor MGT Stages • Stage I – less than <3cm and localized • Stage II – 3-5 cm and localized • Stage III - >5cm and localized • Stage IV – any size, metastasis to lymph node • Stage V – any size, distant metastasis

  26. Canine Mammary Gland Tumor MGT Staging • CBC – check for evidence of infection • Profile – hypercalcemia • Aspirate draining lymph node • Thoracic radiographs – 3 views • Abdominal US

  27. Canine Mammary Gland Tumor MGT Staging • CBC – check for evidence of infection • Profile – hypercalcemia • Aspirate draining lymph node • Thoracic radiographs – 3 views • Abdominal US

  28. Canine Mammary Gland Tumor Surgery • As with all masses removed, label margins so they can be read out • Describe the location of the lesion • Mark one end of one direction (e.g., cranial or caudal) with one type suture • Mark one end of the plane 90O to above with another type suture, if necessary • Don’t forget to describe your labeling on the submission form

  29. Canine Mammary Gland Tumor Surgery – OHE? • The majority of MGT of epithelial origin express estrogen receptors, suggesting that reproductive hormones may play a role in the pathogenesis • 755 days median survival - dogs spayed at or within 2 years before MGT surgery • 286 days median survival – dogs not spayed at MGT surgery • 301 days median survival – dogs spayed more than 2 years prior to MGT surgery MGT are uncommon in females spayed more than 2 years prior to MGT, but if it occurs, it behaves more malignantly

  30. Canine Mammary Gland Tumor Prognosis • 50-60% of mammary gland tumors are benign • 98% of tumors <1 cm are benign • 50% of tumors >3cm are malignant • Malignant tumors develop from benign masses • Early removal is usually curative

  31. Canine Mammary Gland Tumor Inflammatory Mammary Carcinoma • Acute onset of painful, extensive swelling of the mammary glands • Fine needle aspiration with a 25g needle can drip blood for days (DIC) • Rapidly progressive • Grave prognosis

  32. Perianal Tumors • “aka” hepatoid tumor • Most common in older intact male dogs • And females with testosterone producing adrenal tumors • Tumor site – perineum > tail, abdomen • Most often found without symptoms • Tenesmus can be caused by the lesion or submandibular lymphadenopathy (palpable rectally) • 60-80% benign • Those that are malignant often behave as anal sac tumors

  33. Perianal Tumors • Staging prior to surgery • Abdominal rads and/or sonography to evaluate sublumbar lymph nodes • Large tumors >2cm and single tumors should be removed • If multiple small tumors or coalescing tumors, castrate first (if male) • Remove any tumors that do not resolve in 2-4 weeks • Unless males are castrated, new tumors will likely arise

  34. Anal Sac Carcinoma • Highly malignant • Locally invasive AND distant metastases • 90% develop hypercalcemia • 25-50% are hypercalcemic at diagnosis • 50-94% have lymph node metastasis at the time of diagnosis

  35. Anal Sac Carcinoma Presentation • Found on anal sac expression • Dyschezia, tenesmus, ribbon-like stools • Attention to the perineum, scooting • Perianal bleeding • PU-PD (hypercalcemia) • Hind limb weakness or posterior paralysis • May be bilateral – check the other side

  36. Anal Sac Carcinoma Staging • Profile – hypercalcemia, azotemia • Abdominal rads and/or sonography • Sonography more sensitive than rectal palpation or rads for finding enlarged sublumbar LN • Thoracic radiographs – 3 views • Aspirate popliteal and inguinal lymph nodes • Sublumbar if large enough and you are comfortable doing this with ultrasound guidance

  37. Anal Sac Carcinoma Median Survival – no treatment • 7-9 months • masses larger than 3cm • Dogs with hypercalcemia and/or pulmonary metastasis • 18-19 months • Masses smaller than 3cm • Dogs with normocalcemia and no lung mets

  38. Anal Sac Carcinoma Median Survival • Surgery only • 90% survival at 6 months (hypercalcemia often goes into remission, even if incomplete excision) • 65% survival at one year • 29% survival at 2 years • 20% temporary fecal incontinence, some permanent • Wound infection and sepsis can occur • 30% perioperative fatality when sublumbar lymph nodes are removed

  39. Anal Sac Carcinoma Median Survival • Multi-modal therapy – surgery, radiation of nodes, doxorubicin/carboplatin • 18-26 months median survival • 86% survival at 6 months (less than surgery alone) • 69% survival at one year (same as surgery alone) • 36% survival at 2 years (more than surgery alone) • 14% survival at 3 years • Median survival 22 months with radiation alone • 15% rectal structure

  40. Acknowledgements • Jane M. Dobson, MA, BVetMed, DVetMed, DECVIM-CA&Onc, MRCVS Department of Veterinary Medicine, University of Cambridge, Cambridge, UK • Deborah W. Knapp, DVM, DACVIM (Oncology)Purdue University, West Lafayette, IN, USA • Karin Ulrikke Sorenmo, DVM, DACVIM, DECVIM-CA (Oncology)Veterinary Hospital of the University of PennsylvaniaPhiladelphia, PA, USA

  41. Acknowledgements • Erik Teske, DVM, PhD, Dip ECVIM-CAClinical Sciences, Companion AnimalsUtrecht University, THE NETHERLANDS • Katherine Skorupski, DVM, DACVIM (Oncology)Assistant Professor of Clinical Medical OncologyUniversity of California, Davis • Greg Ogilvie, DVM, DACVIM (Oncology) Director, Angel Care Cancer Center, California

More Related